Long-term Clinical Outcomes in Visceral Leishmaniasis-HIV Co-infected Patients during and after Pentamidine Secondary Prophylaxis in Ethiopia: a single-arm clinical trial
dc.contributor.author | Diro, E | |
dc.contributor.author | Ritmeijer, K | |
dc.contributor.author | Boelaert, M | |
dc.contributor.author | Alves, F | |
dc.contributor.author | Mohammed, R | |
dc.contributor.author | Abongomera, C | |
dc.contributor.author | Ravinetto, R | |
dc.contributor.author | De Crop, M | |
dc.contributor.author | Fikre, H | |
dc.contributor.author | Adera, C | |
dc.contributor.author | van Loen, H | |
dc.contributor.author | Tsoumanis, A | |
dc.contributor.author | Adriaensen, W | |
dc.contributor.author | Hailu, A | |
dc.contributor.author | van Griensven, J | |
dc.date.accessioned | 2017-10-24T14:00:30Z | |
dc.date.available | 2017-10-24T14:00:30Z | |
dc.date.issued | 2017-09-13 | |
dc.date.submitted | 2017-10-18 | |
dc.identifier.citation | Long-term Clinical Outcomes in Visceral Leishmaniasis-HIV Co-infected Patients during and after Pentamidine Secondary Prophylaxis in Ethiopia: a single-arm clinical trial. 2017 Clin. Infect. Dis. | en |
dc.identifier.issn | 1537-6591 | |
dc.identifier.pmid | 29020217 | |
dc.identifier.doi | 10.1093/cid/cix807 | |
dc.identifier.uri | http://hdl.handle.net/10144/619029 | |
dc.description.abstract | We have conducted a single-arm trial evaluating monthly pentamidine secondary prophylaxis (PSP) to prevent visceral leishmaniasis (VL) relapse in Ethiopian HIV-patients. Outcomes at 12 months of PSP have been previously reported, supporting PSP effectiveness and safety. However, remaining relapse-free after PSP discontinuation is vital. We now report outcomes and associated factors for a period of upto 2.5 years after initiating PSP, including one year follow-up after PSP discontinuation. | |
dc.language.iso | en | en |
dc.publisher | Oxford University Press | en |
dc.rights | Archived with thanks to Clinical Infectious Diseases : an official publication of the Infectious Diseases Society of America | en |
dc.title | Long-term Clinical Outcomes in Visceral Leishmaniasis-HIV Co-infected Patients during and after Pentamidine Secondary Prophylaxis in Ethiopia: a single-arm clinical trial | en |
dc.identifier.journal | Clinical Infectious Diseases : an official publication of the Infectious Diseases Society of America | en |
refterms.dateFOA | 2019-03-04T13:38:23Z | |
html.description.abstract | We have conducted a single-arm trial evaluating monthly pentamidine secondary prophylaxis (PSP) to prevent visceral leishmaniasis (VL) relapse in Ethiopian HIV-patients. Outcomes at 12 months of PSP have been previously reported, supporting PSP effectiveness and safety. However, remaining relapse-free after PSP discontinuation is vital. We now report outcomes and associated factors for a period of upto 2.5 years after initiating PSP, including one year follow-up after PSP discontinuation. |